Exhibit 10.46

 

	
Confidential   Treatment Requested
   Under 17 C.F.R. §§ 200.80(b)(4) and
   240.24b-2
    	

    


 

CHANGE ORDER

 

AMENDED LETTER OF PAYMENT AUTHORIZATION

 

Amendment No. 01

 

January 20th, 2012

 

Gary Hattersley, Ph.D.

Vice President, Biology

RADIUS HEALTH, INC.

5th Floor

300 Technology Square

Cambridge, MA 02139

United States

ghattersley@radiuspharm.com

 

	
RE:
    	
 
    	
STUDY   PN 670364
    (Radius No:10RAD032)
    	
 
    	
Study   Title: A 2-Year Subcutaneous Injection Carcinogenicity   Study Of BA058 And PTH In The Fisher 344 Rat
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
AS PER   FINAL PROTOCOL DATED:      December 29, 2010

AS   PER PROTOCOL AMENDMENT # 1, 2 and 5

 

STUDY   START: Week of January 17, 2010
    


 

Dear Gary,

 

This communication is to serve as an Amended Letter of Payment Authorization (ALOPA) for the above referenced study, which will be performed at Charles River Laboratories Preclinical Services as set forth below.  Charles River Laboratories Preclinical Services shall perform these services in accordance with the existing Service Agreement executed between Charles River Laboratories Preclinical Services and RADIUS HEALTH, INC. Once fully executed, this ALOPA shall be incorporated into and made part of the existing Service Agreement.

 

Summary of Changes:

 

· 48 animals added for TK population

· Blood smear evaluation added

· 1 time point of TK removed

· TK analysis removed

· Histopathology on TK animals removed

· 7 tissues added for histopathology

· ADA sampling added

· 5 occasions of dose analysis added

· 30 spare animals removed

· Acclimation extended by 1 week

· Pharmacy preparation modified

· Organ weight report removed

· PTH 1-34 analysis added for Group 5 sample

 




[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

1











 

The price of this Protocol Amendment is as follows:

 

	
Authorized   Price

(After   discount)
    	
 
    	
$ [*]

(as   per signed LOPA dated: November 16, 2010)
    
	
 
    	
 
    	
 
    
	
Additional   Charge
    	
 
    	
$ [*]
    
	
 
    	
 
    	
 
    
	
Additional   with additional [*]% goodwill discount:
    	
 
    	
$ [*]
    
	
 
    	
 
    	
 
    
	
Revised   Price
    	
 
    	
$ 2,489,035 US
    


 

The payment schedules of this study are as follows:

 

·$ [*] First payment at study authorization

·75% Equal monthly installments

·Additional Charge  Due upon receipt of invoice

·5% Upon receipt of draft report

·5% Upon receipt of final report or forty five (45) days after issuance of draft report (whichever comes first)

 

Please sign and return this document via facsimile or email (contact information below).  Should you have any questions or require any additional information, please do not hesitate to call me.  We look forward to being of service.

 

Best regards,

 

	
/s/   Stéphane Besner
    	
 
    	
 
    
	
Stéphane   Besner, B.Sc. M.B.A
    	
 
    	
/s/   B. Nicholas Harvey
    
	
Senior   Client Manager, Sales & Marketing
    	
 
    	
Authorized   Sponsor Representative
    
	
Charles River Laboratoires
    	
 
    	
 
    
	
Preclinical Services Montreal Inc.
    	
 
    	
B.   Nicholas Harvey, Chief Financial Officer
    
	
22022 Transcanadienne
    	
 
    	
Print   (Name and Title)
    
	
Senneville, Québec, Canada H9X 3R3
    	
 
    	
 
    
	
Tel:   (514) 630-2436 Fax: (514) 630-8230
    	
 
    	
January 20,   2012
    
	
e-mail:stephane.besner@crl.com
    	
 
    	
Date
    
	
Web   site: www.criver.com
    	
 
    	
 
    


 

If a PO is required, please submit PO with Letter of Payment Authorization or fax to 514-630-8230.

 

c.c. S. Pryce, D. Tremblay, S Y. Smith, B. Attella, Main File

CRT: 22633, 22708, 22709, 22748, 23477

V:\CLIENTS\Radius\2012\670364.L6.20Jan12 - ALOPA1.doc

 




[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

2